Life Science strategy – implementation via thematic groups

Sweden's national life science strategy, published at the end of 2019, will now be translated into action. SwedenBIO pushes for this by being active in all of the thematic groups that during the period 2020-2022 will work to achieve the various objectives set by the strategy.

COVID-19 and community resilience

The theme group is led by SwedenBIO’s Vice Chair Lotta Ljungqvist, CEO of Testa Center. SwedenBIO is represented by Janet Hoogstraate, Valneva.

Precision medicine and ATMP

SwedenBIO is represented by Johan Hyllner, Head of Cell Therapy Department at AstraZeneca.

Health data

SwedenBIO is represented by Björn Arvidsson, Director of STUNS Life Science and chairman of SwedenBIO’s internal working group for Public Affairs.

Input and documents

Input to the R&I proposal input
Action plan from SwedenBIO, LIF and Swedish Medtech
Input on international brightness and attractiveness
Precision medicine input